Contrasting Mesoblast (NASDAQ:MESO) & Krystal Biotech (KRYS)

Mesoblast ( NASDAQ:MESO ) and Krystal Biotech ( NASDAQ:KRYS ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for Mesoblast and Krystal Biotech, as provided by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 0 4 0 2.60 Krystal Biotech 0 0 6 0 3.00 Mesoblast presently has a consensus price target of $13.30, suggesting a potential upside of 211.48%. Krystal Biotech has a consensus price target of $34.75, suggesting a potential upside of 50.24%. Given Mesoblast’s higher possible upside, research analysts plainly believe Mesoblast is more favorable than Krystal Biotech.

Profitability

This table compares Mesoblast and Krystal Biotech’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Mesoblast -171.79% -12.90% -10.44% Krystal Biotech N/A -17.92% -17.56% Insider and Institutional Ownership

3.0% of Mesoblast shares are held by institutional investors. Comparatively, 18.9% of Krystal Biotech shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 45.8% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Mesoblast has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

Valuation & Earnings

This table compares Mesoblast and Krystal Biotech’s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.34 million 23.19 -$35.29 million ($0.63) -6.78 Krystal Biotech N/A N/A -$7.92 million ($1.48) -15.63 Krystal Biotech has lower revenue, but higher earnings than Mesoblast. Krystal Biotech is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company’s products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Krystal Biotech Company Profile Krystal Biotech logo Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company’s lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.

Receive News & Ratings for Mesoblast Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mesoblast and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *